Plaque

BioVie’s NE3107 Demonstrates Potential Improvements in Motor and Non-motor Symptoms for Parkinson’s Disease Patients and May Be Realigning Physiological Processes for Alzheimer’s Patients in Data to be Presented at the International Conference on Alzheime

Retrieved on: 
Friday, March 1, 2024

CARSON CITY, Nev., March 01, 2024 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced two upcoming presentations at the International Conference on Alzheimer’s and Parkinson’s Diseases 2024 (AD/PD™ 2024) to be held March 5-9, 2024 in Lisbon, Portugal.

Key Points: 
  • These findings complement previously reported improvement in motor symptoms in patients treated with NE3107 and demonstrate potential intrinsic, levodopa-enhancing activity of NE3107 that is consistent with data from animal models.
  • NE3107-treated patients experienced a significant improvement of -2.4 points for the sleep/fatigue domain of the Non-Motor Symptom Scale (NMSS) in Parkinson’s Disease, whereas placebo patients experienced a worsening of +1.0 points (p=0.0159).
  • Sleep/fatigue domain improvements correlated with motor score improvements (r=0.51; p=0.0259).
  • More patients on NE3107 had improvements in the NMSS sleep/fatigue domain, while more patients on placebo worsened.

Gaxos Health Forms Medical Advisory Board to Support Launch of AI-powered Health and Wellness Solution

Retrieved on: 
Wednesday, February 28, 2024

“The establishment of our Medical Advisory Board reflects our commitment to pursuing a best-in-class solution for Gaxos Health,” said Vadim Mats, CEO of Gaxos.AI.

Key Points: 
  • “The establishment of our Medical Advisory Board reflects our commitment to pursuing a best-in-class solution for Gaxos Health,” said Vadim Mats, CEO of Gaxos.AI.
  • He is an attending cardiologist at Hackensack University Medical Center’s Heart and Vascular Hospital where he is director of lipids and preventive cardiology.
  • Dr. Lebowitz received his MD from Cornell University Medical College (now Weill-Cornell Medical College) in New York.
  • “We welcome Dr. Lebowitz to the advisory board as his experience and talents will be invaluable to the creation of our solution,” Vadim Mats added.

Canon Solutions America Recognized by William Paterson University for Contributions to Russ Berrie Institute for Professional Sales

Retrieved on: 
Tuesday, February 20, 2024

Education—and the enhancement of the next generation of business leaders—is a strong focus point for Canon Solutions America.

Key Points: 
  • Education—and the enhancement of the next generation of business leaders—is a strong focus point for Canon Solutions America.
  • To that end, the company has provided support for both William Paterson’s Russ Berrie Institute for Professional Sales and the annual competition, with high-ranking and experienced sales employees offering valuable instruction to students interested in the sales profession.
  • Additionally, Canon Solutions America personnel have also served as judges for the contest, including Michael Mellusi, vice president, Sales, Workplace Technologies and Services.
  • Two current Canon Solutions America sales representatives in Roseland, New Jersey are William Paterson graduates and alumni of the Russ Berrie Institute for Professional Sales.

VTYX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Ventyx Biosciences, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

Retrieved on: 
Tuesday, March 5, 2024

Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Ventyx Biosciences, Inc. (“Ventyx” or “the Company”) (NASDAQ: VTYX) and certain of its officers.

Key Points: 
  • Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Ventyx Biosciences, Inc. (“Ventyx” or “the Company”) (NASDAQ: VTYX) and certain of its officers.
  • Ventyx is a clinical-stage biopharmaceutical company that develops small molecule product candidates to address a range of inflammatory diseases.
  • The Company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease.
  • Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits.

Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of Ventyx Biosciences, Inc. (VTYX) Investors

Retrieved on: 
Monday, March 4, 2024

Investors have until April 30, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Key Points: 
  • Investors have until April 30, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
  • On November 6, 2023, Ventyx issued a press release announcing results from its Phase 2 SERENITY Trial.
  • Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation.
  • The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars.

Wilson Sonsini London Teams Up With the National Baseball Hall of Fame and Museum to Feature Historic Photos of “America’s National Pastime” as Part of Themed Office Décor Concept

Retrieved on: 
Monday, February 26, 2024

The new office features historic photographs of legendary baseball venues and players, courtesy of the firm’s new partnership with the National Baseball Hall of Fame and Museum in Cooperstown, New York.

Key Points: 
  • The new office features historic photographs of legendary baseball venues and players, courtesy of the firm’s new partnership with the National Baseball Hall of Fame and Museum in Cooperstown, New York.
  • View the full release here: https://www.businesswire.com/news/home/20240225711073/en/
    The collaboration allows Wilson Sonsini to highlight its transatlantic focus: supporting UK and other European technology companies as they look to access the American commercial and capital markets.
  • Wilson Sonsini officially opened its new London office on Monday, February 19.
  • Since first opening a London office in 2018 with a single US partner on Old Street , Wilson Sonsini has grown and built upon its distinctive position in the London legal market.

Compilation of quality review of documents (QRD) on stylistic matters in product information

Retrieved on: 
Sunday, March 10, 2024

29 February 2024

Key Points: 
    • 29 February 2024
      EMA/25090/2002 rev.23*
      Human Medicines Division

      Compilation of QRD decisions on stylistic matters in product information
      Issues
      Abbreviations

      Connected problems
      Subscript and superscript

      QRD Suggestions
      Acronyms must be written in their standard form; e.g.

    • Cmax, Cmax
      Abbreviations and

      Not always understood,

      Non-standard abbreviations and acronyms should be avoided, and the term should be written out in full.

    • The same applies when stating the pharmaceutical form in section 3 of the SmPC and section 4 of the labelling;
      i.e.
    • critical steps prior to administration of the product should also be included (section 5 of Annex IIIA).
    • Compilation of QRD decisions on stylistic matters in product information
      EMA/25090/2002

      Page 2/23

      Issues

      Connected problems

      QRD Suggestions

      emphasise in the labelling
      the special handling prior
      to administration of the
      product.

    • Consistency

      Inconsistencies in style are

      Once a particular style or house style has been selected, it must be used consistently throughout the text.

    • Tradename 150 mg solution for injection in pre-filled syringe
      Tradename 150 mg solution for injection in pre-filled pen

      information annexes?

    • Compilation of QRD decisions on stylistic matters in product information
      EMA/25090/2002

      Page 3/23

      Issues
      Desiccant

      Connected problems

      QRD Suggestions

      For medicinal products

      The foil of blister packs containing a desiccant must be clearly labelled to show which blister pocket contains

      packaged with a desiccant

      the desiccant.

    • For bottles containing a desiccant, a similar statement should also be considered provided there

      mistake the desiccant for a

      is available space.

    • It can only be included in brackets in section 3 of the

      where can this be

      SmPC and section 4 of the labelling.

    • Direct speech should only
      be used in section 6 of the SmPC for instructions about shelf-life, storage, handling and disposal.
    • The term ?drug? though can be used in the product information annexes when it is part of a standard set of
      terms (e.g.
    • Compilation of QRD decisions on stylistic matters in product information
      EMA/25090/2002

      Page 5/23

      Issues
      Foreign terms

      Connected problems

      QRD Suggestions

      Foreign terms, particularly

      Foreign terms must be written in italics; e.g.

    • Patients can be referred to as ?he? or

      physician is often referred

      as ?she? when the medicinal product is exclusively for use by males or females.

    • if the product in question might be

      measurements are

      used by elderly patients), in brackets after the metric measures in the English text.

    • Compilation of QRD decisions on stylistic matters in product information
      EMA/25090/2002

      Page 6/23

      Issues

      Connected problems

      QRD Suggestions

      product name is composed
      of MAH+INN?

    • Compilation of QRD decisions on stylistic matters in product information
      EMA/25090/2002

      Page 7/23

      Issues

      Connected problems

      QRD Suggestions
      MT: English
      BG: Bulgarian
      NL: Dutch
      CZ: Czech or English at applicant?s discretion.

    • Compilation of QRD decisions on stylistic matters in product information
      EMA/25090/2002

      Page 14/23

      Issues

      Connected problems

      QRD Suggestions
      considered, e.g.

    • Compilation of QRD decisions on stylistic matters in product information
      EMA/25090/2002

      Page 16/23

      Issues
      Symbols: Non-Unicode

      Connected problems

      QRD Suggestions

      The use of non-Unicode

      Only Unicode symbols must be used in submitted product information annexes.

    • Compilation of QRD decisions on stylistic matters in product information
      EMA/25090/2002

      Page 20/23

      Issues

      Connected problems

      Units: SI base units -

      International Standard

      litre

      base units have been
      introduced in the European
      Union with Council
      Directive 80/181/EEC of
      20.12.79 (O.J.

    • Compilation of QRD decisions on stylistic matters in product information
      EMA/25090/2002

      Page 23/23

Advancing Healthcare Access: Genesis MedTech Teams Up with Silk Road Medical to Serve Patients affected by Carotid Artery Disease in China

Retrieved on: 
Friday, March 8, 2024

TCAR (Transcarotid Artery Revascularization) is an innovative minimally invasive surgical procedure used to treat carotid artery disease, a condition characterized by the narrowing or blockage of the carotid arteries in the neck.

Key Points: 
  • TCAR (Transcarotid Artery Revascularization) is an innovative minimally invasive surgical procedure used to treat carotid artery disease, a condition characterized by the narrowing or blockage of the carotid arteries in the neck.
  • Since its establishment in 2019, Genesis MedTech Group has continuously strived to enhance its peripheral interventional portfolio, offering comprehensive solutions to both physicians and patients.
  • Before the introduction of TCAR, moderate to severe carotid artery disease was generally treated clinically with two surgical methods: Carotid Endarterectomy (CEA) and Transfemoral Carotid Artery Stenting (TFCAS).
  • Together with Silk Road Medical, we remain dedicated to make better healthcare more accessible, improving patient care and outcomes."

Boston Scientific Receives FDA Approval for the AGENT™ Drug-Coated Balloon

Retrieved on: 
Friday, March 1, 2024

MARLBOROUGH, Mass., March 1, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced it has received U.S. Food and Drug Administration (FDA) approval for the AGENT™ Drug-Coated Balloon (DCB), which is indicated to treat coronary in-stent restenosis (ISR) in patients with coronary artery disease. ISR is the obstruction or narrowing of a stented vessel by plaque or scar tissue.

Key Points: 
  • First coronary drug-coated balloon in U.S. provides safe, effective alternative to treat coronary in-stent restenosis and reduce risk of reoccurrence
    MARLBOROUGH, Mass., March 1, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced it has received U.S. Food and Drug Administration (FDA) approval for the AGENT™ Drug-Coated Balloon (DCB), which is indicated to treat coronary in-stent restenosis (ISR) in patients with coronary artery disease.
  • ISR is the obstruction or narrowing of a stented vessel by plaque or scar tissue.
  • Experience the full interactive Multichannel News Release here: https://www.multivu.com/players/English/9029352-boston-scientific-fda-ap...
    "With more than 100,000 patients treated globally to date in both clinical and commercial settings, we are very pleased to introduce this proven therapy as the first drug-coated coronary balloon in the U.S," said Lance Bates, president, Interventional Cardiology Therapies, Boston Scientific.
  • Boston Scientific plans to launch the technology in the U.S. in the coming months.

M&T Charitable Foundation Gives $100,000 Grant to the Jackie Robinson Foundation, Advancing Its Mission to Educate, Inspire, and Empower

Retrieved on: 
Thursday, February 29, 2024

NEW YORK, Feb. 29, 2024 /PRNewswire/ -- The M&T Bank Charitable Foundation has announced a $100,000 grant allocated to the Jackie Robinson Foundation. This funding will support the Foundation's programmatic services dedicated to JRF Scholars within the greater New York City Area. These services include career guidance, internship facilitation, permanent job placement assistance, as well as leadership development and practical life skills.

Key Points: 
  • NEW YORK, Feb. 29, 2024 /PRNewswire/ -- The M&T Bank Charitable Foundation has announced a $100,000 grant allocated to the Jackie Robinson Foundation.
  • The Jackie Robinson Foundation (JRF) administers one of the nation's premier scholarship and leadership development programs for minority college students.
  • The Jackie Robinson Museum is a museum and educational center in Manhattan that honors the legacy of Jackie Robinson.
  • For more information on the M&T Charitable Foundation, please visit the M&T Charitable Foundation website .